Roche dumps Repare's synthetic lethal drug days after making $40M stitch in Tapistry trial

Roche has made a fast U-turn on Repare Therapeutics’ synthetic lethal drug candidate. Days after dosing a phase 2 patient and triggering a $40 million payment, Roche told the oncology biotech that it will hand back the asset following a review of its pipeline and “evolving external factors.”